deltatrials
Completed PHASE2 INTERVENTIONAL 5-arm NCT03802565

Tolperisone in Acute Muscle Spasm of the Back (STAR)

Dose Ranging Study of Tolperisone in Acute Muscle Spasm of the Back

Sponsor: Neurana Pharmaceuticals, Inc.

Conditions Acute Pain Back Pain Back Spasm Upper Back Back Strain Low Back Pain Muscle Cramp Muscle Spasm
Interventions Placebo Tolperisone
Updated 13 times since 2019 Last updated: Jan 28, 2022 Started: Feb 1, 2019 Primary completion: Jun 28, 2019 Completion: Jul 12, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03802565, this PHASE2 trial focuses on Acute Pain and Back Pain and remains completed. Sponsored by Neurana Pharmaceuticals, Inc., it has been updated 13 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Jul 2019 · 3 months · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Dec 2020 · 14 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Feb 2022 · 10 months · monthly snapshot~Feb 2022 – ~Jul 2024 · 29 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Feb 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Apr 2021 — Feb 2022 [monthly]

    Completed PHASE2

▶ Show 8 earlier versions

  1. Jan 2021 — Apr 2021 [monthly]

    Completed PHASE2

  2. Dec 2020 — Jan 2021 [monthly]

    Completed PHASE2

  3. Oct 2019 — Dec 2020 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Aug 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Apr 2019 — Jul 2019 [monthly]

    Recruiting PHASE2

  7. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE2

  8. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Neurana Pharmaceuticals, Inc.
Data source: Neurana Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Ann Arbor, United States , Atlanta, United States , Baytown, United States , Bryan, United States , Cincinnati, United States , Cleveland, United States , Dayton, United States , Edgewater, United States , Edgewood, United States and 32 more locations